Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All drugs

Osugacestat (AL101, BMS-906024)

Stage Phase 2

Sponsor Ayala Pharmaceuticals

Class gamma secretase inhibitor

Mechanism pan-NOTCH inhibition via gamma secretase

Target NOTCH1 to 4 (gamma secretase)

Sources

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT03691207

ACCURACY (AL101, osugacestat, gamma secretase inhibitor), NCT03691207, results posted 01.31.2024 (registry; opened 2026-10-27): NOTCH1 to 4 activating mutation required; Cohort 1 AL101 4 mg (n 45) ORR 3 responders, Cohort 2 6 mg (n 42) 2 responders; clinical benefit response 28 and 24 participants; median OS 9.3 months (6.6 to 14.2) and 9.4 months (5.9 to 11.9); serious AEs 23 of 45 and 26 of 42. ESMO 2023 abstract 903P (doi 10.1016/j.annonc.2023.09.2048) and ASCO 2022 abstract 6046 not opened; a 7% discontinuation rate in the search record is not verified. Identification: osugacestat is BMS-906024 (PMC4434460; NCI EVS C116872). AL102 is varegacestat, a different gamma secretase inhibitor for desmoid tumors (Immunome release on the NDA, opened earlier this run).

Brief source A18

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT03691207

A Phase 2, Open-Label, Multi-center Study of AL101 in Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

ACCURACY

Registry NCT03691207

Phase Phase 2

Status Completed

Enrollment 87

Start 2018-12-14

Primary completion 2022-07-15

Study completion 2022-12-02

AL101 4 mg

Dose 4 mg

Population R/M ACC with NOTCH1 to 4 activating mutation (n = 45)

Estimand Single arm

responders (CR or PR): 3 patients (of 45), final, results posted 01.31.2024

median overall survival: 9.3 months, final

patients with serious adverse events: 23 patients (of 45), final

AL101 6 mg

Dose 6 mg

Population R/M ACC with NOTCH activating mutation (n = 42)

Estimand Single arm

responders (CR or PR): 2 patients (of 42), final

median overall survival: 9.4 months, final

patients with serious adverse events: 26 patients (of 42), final